TVTX
Travere Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$65.28
−1.89%Aug 18, 2026, 10:03 UTC
Travere Therapeutics reported that the launch of FILSPARI for focal segmental glomerulosclerosis (FSGS) exceeded expectations, and the company is expanding its renal pipeline.
Source:Aug 4, 2026, 22:16 UTC
Travere Therapeutics reported a second-quarter loss of $0.37 per share, missing the Zacks Consensus Estimate of a loss of $0.14, and compared to a loss of $0.14 per share a year ago.
Jun 16, 2026, 00:00 UTC
William Rote, Ph.D. retired as Chief Research Officer of Travere Therapeutics, effective 2027-02-17.
Jun 4, 2026, 04:00 UTC
Everest Medicines entered into an exclusive licensing and collaboration agreement with Travere Therapeutics for civorebrutinib, a BTK inhibitor for rare kidney diseases.
Source:Jun 2, 2026, 00:00 UTC
Travere Therapeutics entered into a license and collaboration agreement with Everest Medicines to develop and commercialize civorebrutinib (EVER001) outside China and select East and Southeast Asia.